Clinical trial NCT02463409: Theophylline as a Treatment for Children With Pseudohypoparathyroidism Type 1a (Albright Hereditary Osteodystrophy)
Official title: Effects of Theophylline on cAMP Signaling in Children With Pseudohypoparathyroidism Type 1a
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Pseudohypoparathyroidism Type 1a
Albright Hereditary Osteodystrophy
Lead sponsor: Vanderbilt University Medical Center
Sponsor class: OTHER
Collaborators: name: Massachusetts General Hospital
First posted: 2015-06-04
Enrollment: 6
Sex: ALL
Minimum age (years): 10
Maximum age (years): 21
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This study will test an investigational drug, theophylline, in children with pseudohypoparathyroidism type 1a (PHP1a). This study involves a 3 day visit to the Vanderbilt Clinical Research Center.

Detailed description: Study measures will be done at baseline and during a 24h infusion of IV theophylline. Theophylline levels will be drawn to ensure therapeutic dosing and to monitor for toxicity. Measures include laboratory values, response to PTH infusion and resting energy expenditure.

Eligibility criteria: Inclusion Criteria:

1. Age 10 to 21 years old
2. English proficiency
3. Clinical and genetic diagnosis of PHP1a

Exclusion Criteria:

1. Use of a PDE inhibitor in the past 30 days
2. History of a seizure disorder unrelated to hypocalcemia
3. History of a cardiac arrhythmia (not including bradycardia)
4. History of hepatic insufficiency
5. AST or ALT \>2x upper limit of normal
6. Total bilirubin \>1.5 x upper limit of normal (unless patient has a diagnosis of Gilbert's syndrome and no other causes leading to hyperbilirubinemia are identified)
7. Congestive heart failure
8. Cigarette use in the past 30 days
9. Alcohol use within the past 24 hours
10. Current pregnancy
11. Untreated hypothyroidism (defined as free T4 level \< 0.6 ng/dL or TSH \>10 mcU/mL)
12. Active peptic ulcer disease
13. Fever \>101 degrees in the past 24 hours
14. Current use of medications known to effect theophylline levels (listed below)
15. Severe sleep apnea requiring BiPAP

Drugs with clinically significant drug interactions with theophylline:

* Allopurinol
* Cimetidine
* Ciprofloxacin
* Clarithromycin
* Enoxacin
* Ephedrine
* Erythromycin
* Estrogen
* Flurazepam
* Fluvoxamine
* Lithium
* Lorazepam
* Methotrexate
* Midazolam
* Pentoxifylline
* Propranolol
* Rifampin
* Sulfinpyrazone
* Tacrine
* Thiabendazole
* Ticlopidine
* Troleandomycin
* Verapamil

Primary outcomes:
measure: Change in Urine cAMP
timeFrame: 1 day
Secondary outcomes:
measure: Change in Resting Energy Expenditure (REE)
timeFrame: 1 day
measure: Change in Apnea Hypopnea Index (AHI)
timeFrame: 1 day
Other outcomes:
Locations:
city: Nashville
country: United States
facility: Vanderbilt Unversity
state: Tennessee
Study officials:
affiliation: Vanderbilt University
name: Ashley H Shoemaker, MD, MSCI
role: PRINCIPAL_INVESTIGATOR
References:
citation: Landreth H, Malow BA, Shoemaker AH. Increased Prevalence of Sleep Apnea in Children with Pseudohypoparathyroidism Type 1a. Horm Res Paediatr. 2015;84(1):1-5. doi: 10.1159/000381452. Epub 2015 Apr 23.
citation: Shoemaker AH, Lomenick JP, Saville BR, Wang W, Buchowski MS, Cone RD. Energy expenditure in obese children with pseudohypoparathyroidism type 1a. Int J Obes (Lond). 2013 Aug;37(8):1147-53. doi: 10.1038/ijo.2012.200. Epub 2012 Dec 11.